August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Kyle Todd Shared New White Paper Analyzing Clinical Development Trends Across 594 ADCs with 142 Distinct Targets
Jun 25, 2025, 14:17

Kyle Todd Shared New White Paper Analyzing Clinical Development Trends Across 594 ADCs with 142 Distinct Targets

Kyle Todd, Founder and CEO of Zeal Oncology, shared a post on LinkedIn:

“Antibody-Drug Conjugates (ADCs): Expanding the Oncology Target Space
ADCs are no longer trailing traditional antibody therapeutics – they’re leading innovation across oncology, unlocking novel targets, and advancing through clinical development with increasingly sophisticated payloads and formats.
This white paper analyzes clinical development trends across 594 ADCs with 142 distinct targets, highlighting how ADCs are:
• Outpacing other modalities for select targets
• Pursuing targets untouched by other therapeutic classes
• Innovating beyond canonical payloads and antibody formats
Download the full white paper below and follow Zeal Oncology for more insights across the cancer therapeutic landscape!”

Clinical Development

More posts featuring Antibody-Drug Conjugates on OncoDaily.